{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:07:20Z","timestamp":1771232840472,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The healing response of the Firehawk stent in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>We compared the vascular healing of a biodegradable polymer sirolimus-eluting stent (Firehawk) vs. a durable polymer everolimus-eluting stent (Xience) at 6 months after percutaneous coronary intervention (PCI) in patients with STEMI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective, multicenter, randomized, non-inferiority study, patients within 12 h of STEMI onset were randomized in a ratio of 1:1 to receive Firehawk or Xience stents. Optical coherence tomography (OCT) follow-up was performed 6 months after the index procedure and assessed frame by frame. The primary endpoint was the neointimal thickness (NIT) at 6 months evaluated by OCT. The safety endpoint was target lesion failure (TLF) at 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The Firehawk stent was non-inferior to the Xience stent in terms of the neointimal thickness (73.03 \u00b1 33.30 \u03bcm vs. 78.96 \u00b1 33.29 \u03bcm; absolute difference: \u22125.94 [one-sided 95% lower confidence bound: \u221223.09]; <jats:italic>P<\/jats:italic><jats:sub>non\u2212inferiority<\/jats:sub> &amp;lt; 0.001). No significant difference was observed between the Firehawk and Xience groups regarding the percentage of uncovered struts (0.55 [0.08, 1.32]% vs. 0.40 [0.21, 1.19]%, <jats:italic>P<\/jats:italic> = 0.804), the percentage of malapposed struts (0.17 [0.00, 1.52]% vs. 0.17 [0.00, 0.69]%, <jats:italic>P<\/jats:italic> = 0.662), and the healing score (1.56 [0.23, 5.74] vs. 2.12 [0.91, 3.81], <jats:italic>P<\/jats:italic> = 0.647). At 12 months, one patient in the Firehawk group experienced a clinically indicated target lesion revascularization. No other TLF events occurred in both groups. Independent risk factors of the NIT included body mass index, hyperlipidemia, B2\/C lesions, thrombus G3\u2013G5, thrombus aspiration, and postdilation pressure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with STEMI, Firehawk was non-inferior to Xience in vascular healing at 6 months. Both stents exhibited nearly complete strut coverage, moderate neointimal formation, and minimal strut malapposition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Number<\/jats:title><jats:p>NCT04150016.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.895167","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:23:28Z","timestamp":1654082608000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A Randomized Comparison of the Healing Response Between the Firehawk Stent and the Xience Stent in Patients With ST-Segment Elevation Myocardial Infarction at 6 Months of Follow-Up (TARGET STEMI OCT China Trial): An Optical Coherence Tomography Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Yuan","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangjun","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Kan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/01.CIR.0000091115.05480.B0","article-title":"Pathological mechanisms of fatal late coronary stent thrombosis in humans","volume":"108","author":"Farb","year":"2003","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.107.693739","article-title":"Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization","volume":"115","author":"Finn","year":"2007","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2459\/JCM.0000000000000749","article-title":"Stent malapposition, strut coverage and atherothrombotic prolapse after percutaneous coronary interventions in ST-segment elevation myocardial infarction","volume":"20","author":"Leone","year":"2019","journal-title":"J Cardiovasc Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11886-008-0063-8","article-title":"The risks and benefits of drug-eluting stents in the setting of STEMI","volume":"10","author":"Melfi","year":"2008","journal-title":"Curr Cardiol Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/CIRCULATIONAHA.107.762047","article-title":"Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study","volume":"118","author":"Nakazawa","year":"2008","journal-title":"Circulation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCINTERVENTIONS.108.794578","article-title":"Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction","volume":"1","author":"Jensen","year":"2008","journal-title":"Circ Cardiovasc Interv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ijcard.2009.07.012","article-title":"Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study","volume":"146","author":"Kim","year":"2011","journal-title":"Int J Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jcin.2009.01.012","article-title":"Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable\/unstable angina: insights from optical coherence tomography","volume":"2","author":"Gonzalo","year":"2009","journal-title":"JACC Cardiovasc Interv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1161\/CIRCULATIONAHA.110.981688","article-title":"Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction","volume":"123","author":"Dangas","year":"2011","journal-title":"Circulation."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1016\/j.jcin.2017.09.019","article-title":"Observational study of platelet reactivity in patients presenting with ST-segment elevation myocardial infarction due to coronary stent thrombosis undergoing primary percutaneous coronary intervention: results from the european prevention of stent thrombosis by an interdisciplinary global european effort registry","volume":"10","author":"Godschalk","year":"2017","journal-title":"JACC Cardiovasc Interv."},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/CIRCINTERVENTIONS.113.000412","article-title":"Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents- network meta-analysis of primary percutaneous coronary intervention trials in ST-segment\u2013elevation myocardial infarction","volume":"7","author":"Philip","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2014.04.022","article-title":"Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR","volume":"64","author":"Sarno","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","article-title":"Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials","volume":"33","author":"Stefanini","year":"2012","journal-title":"Eur Heart J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jjcc.2017.12.007","article-title":"Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents","volume":"71","author":"Nogic","year":"2018","journal-title":"J Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/ccd.27206","article-title":"Angiographic and clinical performance of polymer-free biolimus-eluting stent in patients with ST-segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study","volume":"91","author":"Sgueglia","year":"2018","journal-title":"Catheter Cardiovasc Interv."},{"key":"B18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"H902","DOI":"10.1152\/ajpheart.00130.2003","article-title":"Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis","volume":"286","author":"Curcio","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1002\/ccd.25335","article-title":"Solely abluminal drug release from coronary stents could possibly improve reendothelialization","volume":"88","author":"Zhang","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jcin.2008.12.012","article-title":"Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing","volume":"2","author":"van der Giessen","year":"2009","journal-title":"JACC Cardiovasc Interv."},{"key":"B22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00019501-200205000-00008","article-title":"Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent","volume":"13","author":"Klugherz","year":"2002","journal-title":"Coron Artery Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0140-6736(18)31649-0","article-title":"Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial","volume":"392","author":"Lansky","year":"2018","journal-title":"Lancet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.4244\/EIJ-D-18-00226","article-title":"Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers","volume":"14","author":"Baumbach","year":"2018","journal-title":"EuroIntervention."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"55","author":"Sousa-Uva","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.4244\/EIJ-D-17-00462","article-title":"First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial","volume":"13","author":"von Birgelen","year":"2018","journal-title":"EuroIntervention."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.jcin.2018.04.038","article-title":"1-year clinical outcomes of all-comer patients treated with the dual-therapy COMBO stent: primary results of the COMBO collaboration","volume":"11","author":"de Winter","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"B29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jacc.2007.04.059","article-title":"Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden","volume":"50","author":"Sianos","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1161\/01.CIR.103.21.2550","article-title":"Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy","volume":"103","author":"Gibson","year":"2001","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/ehjci\/jeu227","article-title":"Comparison of vascular response between everolimus-eluting stent and bare metal stent implantation in ST-segment elevation myocardial infarction assessed by optical coherence tomography","volume":"16","author":"Ino","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.4244\/EIJY15M08_03","article-title":"Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study","volume":"12","author":"Raber","year":"2016","journal-title":"EuroIntervention."},{"key":"B33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ijcard.2012.10.043","article-title":"Comparisons of detailed arterial healing response at seven months following implantation of an everolimus- or sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction","volume":"168","author":"Sawada","year":"2013","journal-title":"Int J Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/eurheartj\/ehs456","article-title":"Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study\u2013TROFI trial","volume":"34","author":"Onuma","year":"2013","journal-title":"Eur Heart J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/ehjci\/jeu042","article-title":"Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study","volume":"15","author":"Garcia-Garcia","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.jcin.2017.07.035","article-title":"Effect of post-dilatation following primary PCI with everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stent implantation: an angiographic and optical coherence tomography TROFI II substudy","volume":"10","author":"Yamaji","year":"2017","journal-title":"JACC Cardiovasc Interv."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1007\/s10554-021-02251-x","article-title":"Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial","volume":"37","author":"Rai","year":"2021","journal-title":"Int J Cardiovasc Imaging."},{"key":"B38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4244\/EIJV9I1A12","article-title":"A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial","volume":"9","author":"Gao","year":"2013","journal-title":"EuroIntervention."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jcin.2019.05.001","article-title":"2-Year clinical outcomes of an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent compared with a durable-polymer everolimus-eluting stent","volume":"12","author":"Xu","year":"2019","journal-title":"JACC Cardiovasc Intervent"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s10554-013-0223-9","article-title":"Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation","volume":"29","author":"Won","year":"2013","journal-title":"Int J Cardiovasc Imaging."},{"key":"B41","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3349\/ymj.2014.55.4.944","article-title":"Optical coherence tomographic observation of morphological features of neointimal tissue after drug-eluting stent implantation","volume":"55","author":"Lee","year":"2014","journal-title":"Yonsei Med J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1161\/01.CIR.0000160363.30639.37","article-title":"Thrombosis modulates arterial drug distribution for drug-eluting stents","volume":"111","author":"Hwang","year":"2005","journal-title":"Circulation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1161\/01.CIR.100.9.918","article-title":"Influence of balloon pressure during stent placement in native coronary arteries on early and late angiographic and clinical outcome: a randomized evaluation of high-pressure inflation","volume":"100","author":"Dirschinger","year":"1999","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"k3793","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.4244\/EIJV12I5A97","article-title":"Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging","volume":"12","author":"Suwannasom","year":"2016","journal-title":"EuroIntervention."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Writing Committee","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.895167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:23:31Z","timestamp":1654082611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.895167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":48,"alternative-id":["10.3389\/fcvm.2022.895167"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.895167","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"895167"}}